Xianglin ShiPrincipal Scientist at Biogen
Xianglin Shi received a B.S. in chemistry from Yanan University and an M.S. under the direction of Prof. Yuqun Chen from Shanghai Institute of Organic Chemistry, the Chinese Academy of Sciences, China. After teaching organic chemistry in Yanan University for six years, he attended Auburn University in Auburn, Alabama, where he completed his M.S. under the direction of Prof. Peter Livant. He then went on to Emory University in Atlanta, Georgia for his Ph.D. under the direction of Prof. Lanny S. Liebeskind and received his Ph.D. in 2000.
He began his industrial process chemistry career in 2000 at Rhodia Chirex, Boston, where he was the leading chemist for the development of several chemical processes. In 2003, he joined the Process Research group at Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts. He held positions of increasing responsibility in process R&D and scale-up for drug intermediates and candidates in early and late stage development. From 2006-2012, he has been a senior and principal scientist in the process chemistry group at Biogen in Cambridge, Massachusetts and been involved in process R&D, scale-up, and CMC activities. Since 2013, he has been engaged in oligonucleotide drug substance process development, validation, manufacturing, and the worldwide new drug application (NDA) for Spinraza Spinraza now has been approved in the USA, Europe, Japan, and China for spinal muscular atrophy (SMA). He has been leading a group responsible for the oligonucleotide synthesis process development and scale-up for manufacturing. His team developed the first 3-reactions per cycle solid-phase synthesis process for manufacturing of phosphorothioate oligonucleotides and is developing a scalable solution phase manufacturing process for oligonucleotides.